Half-year report · Q2
2533.TEDINET S100WH6E
Period2025-01-01 → 2025-06-30
Filed2025-08-06
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥42.3bn | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Revenue | ¥84.1bn | 2024-01-01 → 2024-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥40.2bn | 2024-01-01 → 2024-06-30 | Cons. | Net sales |
| Operating income | ¥2.3bn | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Operating income | ¥1.6bn | 2024-01-01 → 2024-06-30 | Cons. | Operating income |
| Ordinary income | ¥2.4bn | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥3.6bn | 2024-01-01 → 2024-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.7bn | 2024-01-01 → 2024-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.5bn | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.7bn | 2024-01-01 → 2024-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.9bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.3bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.9bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Net income | ¥1.3bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss |
| Total assets | ¥53.9bn | at 2025-06-30 | Cons. | Assets |
| Total assets | ¥55.7bn | at 2024-12-31 | Cons. | Assets |
| Total assets | ¥56.0bn | at 2024-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥28.4bn | at 2025-06-30 | Cons. | Liabilities |
| Total liabilities | ¥31.3bn | at 2024-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥25.5bn | at 2025-06-30 | Cons. | Net assets |
| Net assets / equity | ¥24.5bn | at 2024-12-31 | Cons. | Net assets |
| Net assets / equity | ¥23.3bn | at 2024-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥802m | at 2025-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥887m | at 2024-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥797m | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥882m | at 2024-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥982m | at 2024-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥824m | at 2023-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥377m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥495m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥1.2bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.3bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥752m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.5bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.9bn | 2024-01-01 → 2024-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥414m | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥32.57 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥47.39 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.81 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 45.7% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.4% | at 2024-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.0% | at 2024-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 40
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-01-01 → 2025-06-30 | ¥49m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥44m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-01-01 → 2025-06-30 | ¥6m |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥17m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥17m |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥2.5bn |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥2.5bn |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥568m |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥39.1bn |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥39.0bn |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥12m |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥1.4bn |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥660m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥660m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥389m |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥42.2bn |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥42.2bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥12m |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | ¥2.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-06-30 | ¥46m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-06-30 | ¥41m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥5m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-06-30 | ¥7m |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-06-30 | −¥19m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-06-30 | −¥19m |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥2.2bn |
| jpcrp040300-q2r_E00397-000Enzymatic Medicinereportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥363m |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥37.4bn |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥37.4bn |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥14m |
| jpcrp040300-q2r_E00397-000Liquorreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥903m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥567m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥567m |
| jpcrp040300-q2r_E00397-000Real Estatereportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥298m |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥40.2bn |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥40.2bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥14m |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | ¥1.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 576
| Item | Context | Value | Unit |
|---|---|---|---|
| Depreciation sga | Prior1YTDDuration | 121000000 | JPY |
| Depreciation sga | CurrentYTDDuration | 131000000 | JPY |
| Rent expenses sga | Prior1YTDDuration | 155000000 | JPY |
| Rent expenses sga | CurrentYTDDuration | 161000000 | JPY |
| Amortization of goodwill sga | Prior1YTDDuration | 1000000 | JPY |
| Amortization of goodwill sga | CurrentYTDDuration | 1000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00397-000LiquorReportableSegmentsMember | 37382000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00397-000EnzymaticMedicineReportableSegmentsMember | 2248000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00397-000RealEstateReportableSegmentsMember | 567000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReportableSegmentsMember | 40198000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 41000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 40239000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00397-000LiquorReportableSegmentsMember | 14000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00397-000EnzymaticMedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00397-000RealEstateReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReportableSegmentsMember | 14000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 5000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -19000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00397-000LiquorReportableSegmentsMember | 37396000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00397-000EnzymaticMedicineReportableSegmentsMember | 2248000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00397-000RealEstateReportableSegmentsMember | 567000000 | JPY |
| Net sales | Prior1YTDDuration_ReportableSegmentsMember | 40212000000 | JPY |
| Net sales | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 46000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -19000000 | JPY |
| Net sales | Prior1YTDDuration | 40239000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00397-000LiquorReportableSegmentsMember | 903000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00397-000EnzymaticMedicineReportableSegmentsMember | 363000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00397-000RealEstateReportableSegmentsMember | 298000000 | JPY |
| Operating income | Prior1YTDDuration_ReportableSegmentsMember | 1565000000 | JPY |
| Operating income | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 7000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 1572000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00397-000LiquorReportableSegmentsMember | 39044000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00397-000EnzymaticMedicineReportableSegmentsMember | 2517000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E00397-000RealEstateReportableSegmentsMember | 660000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReportableSegmentsMember | 42223000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 44000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 42268000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00397-000LiquorReportableSegmentsMember | 12000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00397-000EnzymaticMedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E00397-000RealEstateReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_ReportableSegmentsMember | 12000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 5000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -17000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00397-000LiquorReportableSegmentsMember | 39057000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E00397-000EnzymaticMedicineReportableSegmentsMember | 2517000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |